• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Johnson & Johnson

    5/28/25 4:05:16 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email
    SD 1 coverformsd2024.htm SD Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    Form SD


    SPECIALIZED DISCLOSURE REPORT

    Johnson & Johnson

    Johnson & Johnson
    (Exact Name of Registrant as Specified in Charter)

         
    New Jersey 1-3215 22-1024240
    (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number)

    One Johnson & Johnson Plaza
    New Brunswick, New Jersey 08933
    (Address of Principal Executive Offices) (Zip Code)

    Marc Larkins, Corporate Secretary (732) 524-0400


    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

    ý Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.




    Section 1 - Conflict Minerals Disclosure
    Item 1.01 Conflict Minerals Disclosure and Report
    Conflict Minerals Disclosure
    A copy of the Company’s Conflict Minerals Report filed for the calendar year ended December 31, 2024 is publicly available at http://www.investor.jnj.com/governance/sec-filings.cfm. The content of any website referred to in this Form SD, including any exhibit hereto, is included for general information only and is not incorporated by reference in this Form SD.
    Item 1.02 Exhibit
    The Company’s Conflict Minerals Report for the calendar year ended December 31, 2024 is filed as Exhibit 1.01 to this Form SD.


    Section 2 - Exhibits

    Item 2.01 Exhibits

    Exhibit No.        Description
    Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form























    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


     Johnson & Johnson 
      (Registrant) 
    Date:May 28, 2025By:
    /s/ Joseph J. Wolk
     
      Joseph J. Wolk
    Executive Vice President,
    Chief Financial Officer
     









    Get the next $JNJ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    5/30/2024$160.00Neutral
    Goldman
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    12/1/2023$167.00 → $180.00Neutral → Buy
    UBS
    More analyst ratings

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on Johnson & Johnson with a new price target

      BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

      12/10/24 8:28:42 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Johnson & Johnson with a new price target

      Wolfe Research initiated coverage of Johnson & Johnson with a rating of Outperform and set a new price target of $190.00

      11/15/24 8:10:35 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    SEC Filings

    See more
    • Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - JOHNSON & JOHNSON (0000200406) (Filer)

      6/10/25 5:06:51 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Johnson & Johnson

      SD - JOHNSON & JOHNSON (0000200406) (Filer)

      5/28/25 4:05:16 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 13F-HR filed by Johnson & Johnson

      13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

      5/7/25 4:47:35 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care